The Fabry cardiomyopathy - diagnostic approach and current treatment

Current Pharmaceutical Design

Volumn 21, Issue 4, 2015, Pages 473-478

  Weidemann, Frank ^a   Ertl, Georg ^a   Wanner, Christoph ^a   Krämer, Johannes ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cardiomyopathy; Fabry disease; Monitoring; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AORTA VALVE REGURGITATION; ARTICLE; CARDIOMYOPATHY; DISEASE COURSE; ECHOCARDIOGRAPHY; EXERCISE; FABRY CARDIOMYOPATHY; FABRY DISEASE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; CARDIOMYOPATHIES;

CARDIOMYOPATHIES; FABRY DISEASE; HUMANS;

EID: 84925156343     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282104141204142643     Document Type: Article

References (69)

1. [1] Desnick R, Ionnou Y, Eng C. Fabry disease: alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease New York: McGraw Hill 1995; pp. 2741-84.
2. [2] Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28: 1228-35.
3. [3] Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26: 1221-7.
4. [4] Schiffmann R, Kopp JB, Austin HA, III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
5. [5] Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
6. [6] Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
7. [7] Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119: 524-9.
8. [8] Naleschinski D, Arning K, Baron R. Fabry disease-pain doctors have to find the missing ones. Pain 2009; 145: 10-1.
9. [9] Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86.
10. Wanner C: Fabry disease model: a rational approach to the management of Fabry disease. ClinTher 2007; 29 Suppl A:S2-5.
11. [11] Pastores GM, Hughes DA. To see a world in a grain of sand: elucidating the pathophysiology of Anderson-Fabry disease through investigations of a cellular model. Kidney Int 2009; 75: 351-3.
12. [12] Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008; 105: 2812-7.
13. [13] Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24: 2151-5.
14. [14] Sheppard MN, Cane P, Florio R, et al. A detailed pathologic examination of heart tissue from three older patients with Anderson Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 2010; 19: 293-301.
15. [15] Shah JS, Hughes DA, Sachdev B et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol2005; 96: 842-846.
16. [16] Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86.
17. [17] Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert OpinBiolTher 2007; 9: 255-61.
18. [18] Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A PatholAnatHistopathol 1990; 417: 449-55.
19. [19] Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357-60.
20. [20] Barbey F, Brakch N, Linhart A, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. ArteriosclerThrombVascBiol 2006; 26: 839-44.
21. [21] Shen JS, Meng XL, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008; 95: 163-8.
22. [22] Linhart A, Elliott PM: The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93: 528-35.
23. [23] Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll-Cardiol 2002; 40: 1668-74.
24. [24] Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am CollCardiol 2007; 50: 2399-403.
25. [25] Weidemann F, Wanner C, Breunig F. Nomen est Omen. Eur J Echocardiogr 2008; 9: 831-2.
26. [26] Weidemann F, Strotmann JM, Niemann M, et al. Heart Valve Involvement in Fabry Cardiomyopathy. Ultrasound Med Biol 2008; 35: 730-5
27. [27] Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 1978-84.
28. [28] Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
29. [29] Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008; 51:50-9.
30. [30] Krämer J, Niemann M, Liu D et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in fabry disease. Eur Heart J 2013; 34: 1587-96.
31. [31] Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007; 28: 3020-6.
32. [32] Goldman ME, Cantor R, Schwartz MF, et al. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll-Cardiol 1986; 7: 1157-61.
33. [33] Bass JL, Shrivastava S, Grabowski GA, et al. The M-mode echocardiogram in Fabry's disease. Am Heart J 1980; 100: p. 807-12.
34. [34] Barbey F, Qanadli SD, Juli C, et al., Aortic remodelling in Fabry disease. Eur Heart J 2010; 31: 347-53.
35. [35] Mehta A, Ricci R, Widmer U, et al., Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-42.
36. [36] Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003; 63: 46-52.
37. [37] Weidemann F, Strotmann JM, Niemann M, et al., Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol 2009; 35: 730-5.
38. [38] Linhart A, Lubanda JC, Palecek T et al. Cardiac manifestations in Fabry disease. J InheritMetab Dis 2001; 24: 75-83.
39. [39] Niemann M, Breunig F, Beer M, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 2010; 96: 1915-9.
40. [40] Palecek T, Dostalova G, Kuchynka P, et al. Right ventricular involvement in Fabry disease. J Am Soc Echocardiogr 2008; 21: 1265-8.
41. [41] Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll-Cardiol 2002; 40: 1668-74.
42. Strotman J, Breunig F, Wanner C, et al. Progression of Fabry cardiomyopathy. ClinTher 2007; 29 Suppl A: S13-4.
43. [43] Takenaka T, Teraguchi H, Yoshida A, et al.: Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008; 51(1): 50-9.
44. [44] Ueno H, Yokota Y, Yokoyama et al. Comparison of echocardiographic and anatomic measurements of the left ventricular wall thickness. Kobe J Med Sci 1991; 37: 273-86.
45. [45] Niemann M, Liu D, Hu K, et al. Prominent papillary muscles in Fabry disease: a diagnostic marker? Ultrasound Med Biol 2011; 37: 37-43.
46. [46] Calcagnino M, O’Mahony C, Coats C, et al. Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. J Am CollCardiol 2011; 58: 88-9.
47. [47] Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am CollCardiol 2006; 47: 1663-71.
48. [48] Koskenvuo JW, Engblom E, Kantola IM, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance. Clin Physiol Funct Imaging 2009; 29: 177-80.
49. [49] Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am CollCardiol 2008; 51: 2058-61.
50. [50] Mundigler G, Gaggl M, Heinze G, et al. The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. Eur J Echocardiogr 2011; 12: 744-9.
51. [51] Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299-301.
52. [52] Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26: 1221-7.
53. [53] Zamorano J, Serra V, Pérez de Isla L, et al. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011; 12: 671-7.
54. [54] Pieroni M. Echocardiographic assessment of fabry cardiomyopathy: early diagnosis and follow-up. J Am SocEchocardiogr 2011; 24: 1033-6.
55. [55] Gruner C, Verocai F, Carasso S, et al. Systolic Myocardial Mechanics in Patients with Anderson-Fabry Disease with and without Left Ventricular Hypertrophy and in Comparison to nonobstructive Hypertrophic Cardiomyopathy. Echocardiography 2012; 29: 810-7.
56. [56] Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J 2007; 28: 3020-6.
57. [57] Niemann M, Breunig F, Beer M, et al. Tei index in fabry disease. J Am Soc Echocardiogr 2011; 24: 1026-32.
58. [58] Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiopvascular magnetic resonance in a patient with Anderson-Fabry disease. J CardiovascMagnReson 2006; 8: 479-82.
59. [59] Schaefer RM, Tylki-Szymanska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009; 69: 2179-205.
60. [60] Thurberg BL, Fallon JT, Mitchell R, et al. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. 2009; 119: 2561-7.
61. [61] Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153-8.
62. [62] Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. Journal of medical genetics 2009; 46: 548-52.
63. [63] Waldek S, Patel MR, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009; 11: 790-6.
64. [64] Close L, Elliott P. Optimization of concomitant medication in Fabry cardiomyopathy. ActaPaediatrSuppl 2007; 96: 81-3.
65. [65] Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am SocNephrol 2007; 18: 2609-17.
66. [66] Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008; 94: 319-25.
67. [67] Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007; 2: e598.
68. [68] Benichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Molecular genetics and metabolism 2009; 96: 4-12.
69. [69] Radford MJ, Arnold JM, Bennett SJ, et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. Circulation 2005; 112: 1888-916.